Shares of Scienture Holdings, Inc. (NASDAQ:SCNX – Free Report) are scheduled to reverse split before the market opens on Monday, October 5th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 4th.
Scienture Trading Down 31.8%
NASDAQ:SCNX traded down $0.08 during trading hours on Thursday, hitting $0.18. The stock had a trading volume of 1,900,908 shares, compared to its average volume of 2,214,886. The business’s 50 day moving average is $0.37 and its 200-day moving average is $0.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.97 and a current ratio of 3.04. The company has a market cap of $7.27 million, a price-to-earnings ratio of -0.08 and a beta of 3.25. Scienture has a one year low of $0.18 and a one year high of $2.60.
Scienture (NASDAQ:SCNX – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.96 million.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on SCNX
Institutional Investors Weigh In On Scienture
A hedge fund recently bought a new position in Scienture stock. Susquehanna International Group LLP purchased a new position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned approximately 0.57% of Scienture as of its most recent SEC filing. Institutional investors own 5.68% of the company’s stock.
Scienture Company Profile
Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.
Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).
Featured Stories
- Five stocks we like better than Scienture
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
